PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: CHIKV study data published in Peer-Reviewed Journal, page-7

  1. 598 Posts.
    lightbulb Created with Sketch. 138
    I personally don't think it's price sensitive. However it would have looked pretty incompetent declaring it as such when the study was published on the 7th.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.